Modality
mAb
MOA
PRMT5i
Target
JAK2
Pathway
Fibrosis
AngelmanALL
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Jun 2030
Phase 2Current
NCT05175092
826 pts·ALL
2020-05→2027-10·Terminated
NCT06095865
1,569 pts·Angelman
2024-12→2030-06·Recruiting
2,395 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-041.5y awayPh2 Data· ALL
2030-06-034.2y awayPh2 Data· Angelman
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2027-10-04 · 1.5y away
ALL
Ph2 Data
2030-06-03 · 4.2y away
Angelman
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05175092 | Phase 2 | ALL | Terminated | 826 | eGFR |
| NCT06095865 | Phase 2 | Angelman | Recruiting | 1569 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP |